UK markets closed

Ion Beam Applications SA (IOBCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
20.100.00 (0.00%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close20.10
Open20.10
Bid0.00 x 0
Ask0.00 x 0
Day's range20.10 - 20.10
52-week range7.85 - 21.50
Volume32
Avg. volume59
Market cap596.767M
Beta (5Y monthly)0.62
PE ratio (TTM)15.40
EPS (TTM)1.30
Earnings dateN/A
Forward dividend & yield0.09 (0.42%)
Ex-dividend date29 Jun 2020
1y target estN/A
  • Globe Newswire

    IBA – ACQUISITION OF OWN SHARES

    Immediate Release – May 18th, 2021 Louvain-la-Neuve, Belgium, May 18th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12th, 2021. Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel. In the framework of this share buyback program, IBA repurchased 17.290 IBA shares on Euronext Brussels in the period from May 7th, 2021 up to and including May 13th, 2021, as follows: The total number of shares purchased under this program therefore amounts to 334.616. As a result, IBA SA currently holds 808.837 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,68% of its share capital. About IBAIBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com Contact personIBA Christian Matton,Chief Legal Officershareholderrelations@iba-group.com Attachment 20210518_iba_share_buy_back_en

  • Globe Newswire

    IBA – ACQUISITION OF OWN

    Immediate Release – April 15th, 2021 Louvain-la-Neuve, Belgium, April 15th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12th, 2021. Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel. In the framework of this share buyback program, IBA repurchased 19.585 IBA shares on Euronext Brussels in the period from April 9th, 2021 up to and including April 15th, 2021, as follows: The total number of shares purchased under this program therefore amounts to 261.429. As a result, IBA SA currently holds 735.650 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,44% of its share capital. About IBAIBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com Contact personIBA Christian Matton,Chief Legal Officershareholderrelations@iba-group.com Attachment 20210415_iba_share_buy_back_en

  • Globe Newswire

    IBA’s Proteus®ONE selected by Advocate Radiation Oncology for new proton therapy center in Florida

    Louvain-La-Neuve, Belgium, April 07, 2021 – IBA(Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that its Proteus®ONE1 compact proton therapy solution has been selected by Advocate Radiation Oncology in conjunction with its affiliate Southwest Florida Proton for its new radiation oncology center. The site will serve the greater population of Southwest Florida in a centralized location between Lee and Collier County. The parties have signed a binding term sheet for the delivery of IBA’s Proteus®ONE solution including Pencil Beam Scanning (PBS), and a fully integrated quality assurance (QA) hardware and software package from IBA Dosimetry America, Inc. The term sheet includes long-term operation and maintenance services to be provided by IBA. Advocate Radiation Oncology expects to start treating patients by 2023. The typical end-user price for a Proteus®ONE system with a 10-year maintenance contract usually ranges between 40 and 50 million US dollars. Both parties will be working diligently to complete negotiations of the final agreement in the coming months. IBA will start recognizing revenue once the final agreement is executed. Olivier Legrain, Chief Executive Officer of IBA, commented: “As we have highlighted previously, the US is of key strategic importance for our business overall and this latest agreement reinforces our leading position in this market, being our 17th proton therapy system there. The agreement also includes both proton therapy and dosimetry elements, demonstrating the strong synergies between these two business divisions. We look forward to supporting Advocate Radiation Oncology’s world-class practice in providing cancer patients with access to the most advanced radiotherapy technology.” Dr. Arie Dosoretz, Managing Partner at Advocate Radiation Oncology, added: “At Advocate Radiation Oncology, our driving purpose and passion is to provide the most innovative radiation therapy available to the patients who need our help. Exploiting the capabilities of advanced proton therapy is the logical next step in our mission to lead the fight against cancer. We know that IBA’s experience and industry leading technology makes IBA’s Proteus®ONE the clear choice for this endeavor. We are excited to bring a beacon of hope to our community.” ***ENDS*** About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com About Advocate Radiation Oncology Advocate Radiation Oncology is a locally owned practice with convenient locations in South Florida. The practice’s mission is to provide compassionate health care expertise to cancer patients. Advocate Radiation Oncology is directed by a team of world-class, board-certified radiation oncologists,For more information, please visit AdvocateRO.com. CONTACTS Soumya ChandramouliChief Financial Officer+32 10 475 890Investorrelations@iba-group.com Olivier LechienCorporate Communication Direcor+32 10 475 890communication@iba-group.com Consilium Strategic CommunicationsAmber Fennell, Angela Gray, Lucy Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com 1 Proteus®ONE is the brand name of Proteus®235 Attachment 20210407-IBA-Advocate-RO-EN-final